Entera Bio Ltd. ENTX 深 滬
等待開盤 10-21 09:30:00 美东时间
2.47
+0.120
+5.11%
華盛通- 最 高2.53
- 今 開2.36
- 成交量 7.33万股
- 最 低 2.36
- 昨 收 2.35
- 總市值 1.13亿
- 52周最高 2.95
- 市盈率 靜 --
- 換手率 0.16%
- 52周最低 1.5006
- 委 比 58.73%
- 總股本 4566.34万
- 歷史最高 10.16
- 量 比 0.40
- 振 幅 7.23%
- 歷史最低 0.472
- 每 手 1
- 風險率 0.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Entera Bio Announces It Will Present New Phase 2 Clinical Data For EB613 At The North American Menopause Society 2025 Annual Meeting, October 21–25, 2025, In Orlando, Florida.
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its Phase 2 trial of EB613 at the upcoming North
10-16 20:47
Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting
Entera Bio will present Phase 2 data for EB613 at the NAMS 2025 Annual Meeting, focusing on bone mineral density outcomes in early postmenopausal women with low bone mass or osteoporosis. EB613, the first oral anabolic tablet, aims to address the underutilization of injectable anabolic therapies by providing a once-daily treatment option. The study met all biomarker and BMD endpoints, demonstrating increases in lumbar spine, total hip, and femora...
10-16 12:45
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
10-15 20:09
Entera Bio Presents Preclinical Data For OPK-8801003, Oral GLP-2 Tablet With Longer Half-Life Aiming To Replace Daily Injections For Short Bowel Syndrome Patients
Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 TherapyOral GLP-2 Tablet Could Transform Treatment
09-15 21:05
Entera Bio To Present EB613 Phase 2 Data At ASBMR 2025; Oral Anabolic Tablet Advances Toward Phase 3
EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and
09-08 20:33
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
Entrada Therapeutics announced the recipients of its 2025 DREAMS Grant Program, awarding $50,000 each to Jett Foundation (U.S.) and Parent Project aps (Italy). These grants support programs advancing equity, accessibility, and inclusion for individuals with Duchenne muscular dystrophy in the U.S., EU, and U.K. Jett Foundation's Camp Promise provides year-round support for underserved individuals aged 18 and older, while Parent Project aps deliver...
09-05 11:00
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Entrada Therapeutics granted 54,360 RSUs and options to purchase 38,850 shares to seven newly-hired employees under its 2025 Inducement Equity Plan. Options have an exercise price of $5.47 per share, vesting 25% after the first year, with the remaining 75% vesting monthly over three years. RSUs vest 25% after the first year, followed by 6.25% quarterly. The grants aim to incentivize new employees, as approved by the Compensation Committee.
09-02 20:30
Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences
Entera Bio Ltd. will present data on three key programs in September 2025. At the ASBMR Annual Meeting, they will discuss EB613, an oral PTH(1-34) tablet for postmenopausal osteoporosis, and next-gen EB613. At ESPEN, they will present on an oral GLP-2 analog for short bowel syndrome. CEO Miranda Toledano will also provide a corporate overview at the H.C. Wainwright Investor Conference.
08-28 12:00
Entera Bio Q2 EPS $(0.06) Misses $1.21 Estimate
Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $1.21 by 104.96 percent. This is unchanged from the same period last year.
08-09 04:10
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
Entrada Therapeutics reported Q2 2025 financial results and highlighted key milestones, including the first patient dosed in the ELEVATE-44-201 study and initiation of ELEVATE-45-201. Multiple clinical trial sites in the U.K. and EU are activated. The company expanded its leadership team with Navid Khan, PhD, and Kiran Patki, MD, to support its growing pipeline. Cash reserves of $354 million are expected to fund operations into Q2 2027. Data from...
08-06 11:00
